Liu et al. have conducted a comprehensive meta-analysis study in order to evaluate the association between CTLA-4 and the risk of MS, thus clarifying the conflicting results from the individual studies in this field, and they found that 49A/G, 318C/T, or CT60A/G polymorphisms, both in the total analysis and in subgroup analyses, were not found to be significantly associated with MS [148]. The gene discussed is CTLA4; the disease is myeloid sarcoma.